Senti Biosciences, Inc. SNTI
0.33
(0.01)
(2.94%)
as of 25 Sep
- Market cap
- $10.0M
- P/E
- 0.0×
Follow SNTI
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | — | 0.00 |
P/S ratio |
— | 0.00 | 9.02 | 11.20 | — | 8.93 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | — | 0.00 |
P/Operating CF |
— | (2.40) | (4.29) | (4.17) | — | (3.40) |
P/B ratio |
— | 0.00 | 0.30 | 0.44 | — | 4.18 |
Price to Tangible BV |
— | 0.00 | 0.30 | 0.44 | — | 4.18 |
EV/Sales |
— | 0.00 | (13.95) | (2.46) | — | 2.67 |
EV/EBITDA |
— | 0.69 | 1.03 | 0.07 | — | 0.00 |
EV/Operating CF |
— | 0.77 | 1.71 | 0.12 | — | (0.16) |
EV/FCF |
— | 0.77 | 0.78 | 0.10 | — | (0.16) |
Quick Ratio |
— | 3.89 | 5.49 | 4.23 | 3.81 | 1.29 |
Current Ratio |
— | 4.14 | 5.68 | 5.62 | 4.49 | 1.67 |
Net Debt/EBITDA |
— | 1.48 | 1.69 | 0.41 | 0.84 | 0.25 |
Debt/Assets |
0.00% | 0.65% | 0.07% | 0.11% | 0.01% | 0.00% |
Debt/Equity |
— | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.06 | 0.03 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.63 | 0.60 | 0.74 | 0.78 | 0.71 |
Capex/Depreciation |
— | (1.84) | (10.55) | (2.20) | 0.01 | (0.05) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | (736.56%) | (73.19%) | (114.06%) | (393.35%) | |
| — | (114.41%) | (41.95%) | (47.33%) | (48.58%) | (82.43%) | |
ROIC |
— | 0.00% | (134.57%) | (186.22%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (95.35%) | (42.84%) | (84.73%) | (78.67%) | (276.92%) |
Average Days of Receivables |
— | 63.85 | 53.31 | 2,523.22 | 0.00 | 26,462.50 |
Research and Development Expense of Revenue |
— | 795.26% | 656.67% | 1,255.37% | 0.00% | 170,845.45% |
Selling, General and Administrative Expense of Revenue |
— | 769.65% | 891.86% | 1,451.62% | 0.00% | 118,922.73% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 83.12% | 382.45% | 377.59% | 0.00% | 25,936.36% |
Graham Net Nets |
— | (5.15) | 1.27 | 0.64 | — | (0.96) |
Graham Number |
— | 1,279.06 | 0.00 | 0.00 | — | 0.00 |
Earnings Yield |
— | (192.67%) | (363.77%) | (242.06%) | — | (306.73%) |
Free Cash Flow Yield |
— | (120.63%) | (197.36%) | (219.34%) | — | (186.63%) |
Revenue per Share |
— | 9.48 | 1.64 | 0.58 | 0.00 | 0.00 |
Operating CF per Share |
— | (118.94) | (13.36) | (11.81) | (9.01) | (1.93) |
Capex per Share |
— | (19.03) | (15.85) | (2.69) | 0.01 | (0.01) |
Free Cash Flow per Share |
— | (137.97) | (29.21) | (14.50) | (9.00) | (1.94) |
Cash per Share |
— | 192.42 | 37.75 | 8.10 | 10.50 | 0.73 |
Shareholders Equity per Share |
— | (382.75) | 48.74 | 15.08 | 5.58 | 0.25 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (382.75) | 48.74 | 15.08 | 5.58 | 0.25 |
Free Cash Flow |
— | (40.18) | (76.27) | (64.33) | (41.36) | (43.63) |
Working Capital |
— | 45.65 | 84.53 | 58.53 | 45.82 | 9.30 |
Capital Expenditures |
— | (5.54) | (41.37) | (11.93) | 0.03 | (0.18) |
Net Current Asset Value |
— | (147.97) | 49.05 | 18.63 | (13.23) | (22.36) |
EV/EBIT |
— | 0.66 | 0.96 | 0.07 | — | 0.00 |
Capex to Sales |
— | 2.01 | 9.65 | 4.66 | 0.00 | 8.36 |
Net Profit Margin |
— | (2,003.59%) | (1,358.14%) | (2,774.62%) | 0.00% | (279,263.64%) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | 0.24 | 0.08 | 0.21 | 0.18 | 0.28 |
Cash ROIC |
— | 85.78% | (38.17%) | (75.49%) | (84.78%) | (255.94%) |
Accounts Receivable Turnover |
— | 0.00 | 7.73 | 0.28 | 0.00 | 0.01 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 0.55 | 9.17 | 9.75 | 1.70 |
Average Payables |
— | — | 3.28 | 1.31 | 1.35 | 2.20 |
Average Assets |
— | 48.35 | 138.75 | 150.14 | 108.66 | 74.53 |
Average Common Equity |
— | — | 7.90 | 97.09 | 46.28 | 15.62 |
Columns are period end dates